CalciMedica, Inc. (NASDAQ:CALC) CEO Acquires $75,000.00 in Stock

CalciMedica, Inc. (NASDAQ:CALC) CEO A. Rachel Leheny purchased 20,000 shares of CalciMedica stock in a transaction that occurred on Friday, November 1st. The stock was purchased at an average cost of $3.75 per share, for a total transaction of $75,000.00. Following the completion of the purchase, the chief executive officer now owns 130,926 shares of the company’s stock, valued at $490,972.50. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

A. Rachel Leheny also recently made the following trade(s):

• On Tuesday, August 27th, A. Rachel Leheny bought 1,000 shares of CalciMedica stock. The shares were acquired at an average price of $4.19 per share, for a total transaction of $4,190.00.

CalciMedica Price Performance

CALC stock traded down $0.10 during trading on Friday, hitting $3.60. 174,089 shares of the stock traded hands, compared to its average volume of 34,136. The stock has a market cap of $38.70 million, a price-to-earnings ratio of -2.57 and a beta of 1.27. CalciMedica, Inc. has a 1 year low of $2.14 and a 1 year high of $8.38. The firm’s 50 day moving average is $4.27 and its two-hundred day moving average is $4.64.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. As a group, analysts anticipate that CalciMedica, Inc. will post -2.21 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of CalciMedica in a research report on Tuesday, August 13th. Oppenheimer lifted their target price on shares of CalciMedica from $14.00 to $20.00 and gave the company an “outperform” rating in a report on Wednesday, July 10th.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.